Deo Wabwire Ogema
ID: UNCST-2021-R013932
|
COVPN 3008: Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. Version 1.0 16 May 2021
REFNo: HS1659ES
The primary objectives are:
•To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in adults who are at risk of severe COVID-19
•To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19
•To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19
Secondary objectives are to evaluate the following:
•Durability of VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 through the final study visit (Month 12 post-dose 1) in volunteers with no previous COVID-19
•VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19
•VE of COVID-19 mRNA vaccine against SARS-CoV-2 infection defined by nucleocapsid protein seroconversion regardless of symptomology in volunteers with no previous COVID-19
•VE of COVID-19 mRNA vaccine against asymptomatic SARS-CoV-2 infection defined by nucleocapsid protein seroconversion without prior occurrence of the symptomatic COVID-19 primary endpoint in volunteers with no previous COVID-19
•Post -vaccination immune response markers as correlates of risk of COVID-19 and as correlates protection against COVID-19
•VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in all participants regardless of baseline SARS-CoV-2 status
gestational age)
The exploratory objectives are to evaluate:
•VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 by baseline HIV infection status in volunteers with no previous COVID-19 and in all volunteers regardless of previous COVID-19 status
•VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19 and in all volunteers regardless previous COVID-19 status
•VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in volunteers with previous COVID-19
•Relative rate of COVID-19 and severe COVID-19 in placebo recipients with previous COVID-19 compared to vaccine recipients with no previous COVID-19
•Assess T-cell responses in placebo recipients who develop COVID-19 compared to vaccine recipients who develop symptomatic COVID-19
•Assess incidence of adverse birth outcomes among pregnant persons enrolled in the trial
|
Uganda |
2021-08-20 |
2024-08-20 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Edwin Nuwagira
ID: UNCST-2021-R013488
|
Improving Pulmonary function after Tuberculosis (IMPACT) at Mbarara Regional Referral Hospital. The incidence, clinical characteristics and factors associated with post-tuberculosis obstructive pulmonary disease at Mbarara Regional Referral Hospital (MRRH)
REFNo: HS1579ES
To determine the incidence, clinical characteristics and factors associated with post-tuberculosis obstructive pulmonary disease at Mbarara Regional Referral Hospital ,
|
Uganda |
2021-08-20 |
2024-08-20 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Umaru Ssekabira Byansansa
ID:
|
Assessing COVID-19 sero-prevalence from routine antenatal care visits in Moyo and Adjumani Districts, Uganda, 2021-2022
REFNo: HS1628ES
The aim of this activity is to determine COVID-19 sero-prevalence from women attending antenatal clinics for their first ANC visit in Moyo and Adjumani Districts from April 2021 to September 2022.
The specific objectives of this sero-prevalence assessment shall be to:
•Measure the sero-prevalence of antibodies to COVID-19 in the population of pregnant women attending first ANC by age group, in order to ascertain the cumulative population immunity
•Monitor trends and detect emerging hotspots of COVID-19 in selected geographic areas
|
Uganda |
2021-08-20 |
2024-08-20 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Doreen Chemutai
ID:
|
Pathways, Perceptions and Performance: A comparative Analysis of Women on Open and Reserved Seats in Uganda’s 10th Parliament
REFNo: SS971ES
i. To comparatively analyze the motives of women MPs on the reserved and open seats for seeking parliamentary seats in Uganda’s 10th parliament.
ii. To document the experiences of women members of parliament on the reserved and open seats of their journey to parliamentary seats.
iii. To explain voter’s perceptions of performance of women members of parliament on reserved and open seats.
iv. To evaluate the performance differences of women MPs on the reserved and opens seats of representation and legislation
|
Uganda |
2021-08-20 |
2024-08-20 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Annet Nanvubya
ID: UNCST-2025-R015525
|
Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern version 1.0 16-05-2021.
REFNo: HS1677ES
Primary Objectives
The primary objectives of this study are to determine the following:
• To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in adults who are at risk of severe COVID-19
• To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19
• To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19
Secondary Objectives
The secondary objectives of this study are to evaluate the following:
• Durability of VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 through the final study visit (Month 12 post-dose 1) in volunteers with no previous COVID-19
• VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19
• VE of COVID-19 mRNA vaccine against SARS-CoV-2 infection defined by nucleocapsid protein seroconversion regardless of symptomology in volunteers with no previous COVID-19
• VE of COVID-19 mRNA vaccine against asymptomatic SARS-CoV-2 infection defined by nucleocapsid protein seroconversion without prior occurrence of the symptomatic COVID-19 primary endpoint in volunteers with no previous COVID-19
• Post -vaccination immune response markers as correlates of risk of COVID-19 and as correlates protection against COVID-19
• VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in all participants regardless of baseline SARS-CoV-2 status
gestational age)
Exploratory Objectives
The exploratory objectives of this study are to:
• VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 by baseline HIV infection status in volunteers with no previous COVID-19 and in all volunteers regardless of previous COVID-19 status
• VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19 and in all volunteers regardless previous COVID-19 status
• VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in volunteers with previous COVID-19
• Relative rate of COVID-19 and severe COVID-19 in placebo recipients with previous COVID-19 compared to vaccine recipients with no previous COVID-19
• Assess T-cell responses in placebo recipients who develop COVID-19 compared to vaccine recipients who develop symptomatic COVID-19
• Assess incidence of adverse birth outcomes among pregnant persons enrolled in the trial
|
Uganda |
2021-08-20 |
2024-08-20 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Judith Kobusinge
ID:
|
Effect of selected soil moisture conservation practices on water budgeting in Robusta coffee in Uganda
REFNo: A117ES
1) To predict the effect of soil moisture on Robusta coffee production and productivity in Uganda.
2) To estimate the water use efficiency (WUE) of Robusta coffee at various phenological stages under Albizia coriaria and Open sun
3) To determine the effect of selected soil moisture conservation practices on soil-water relations in Robusta coffee agro-systems.
|
Uganda |
2021-08-19 |
2024-08-19 |
Agricultural Sciences |
Non-Clinical Trial |
Degree Award |
|
Patrick OJOK
ID:
|
Teachers’ Perceived Preparedness to Implement the Competency-Based Lower Secondary Curriculum
REFNo: SS810ES
Purpose of the Study
The primary purpose of this study is to determine the perceptions of preparedness of
lower secondary teachers and explore the factors hindering and/or facilitating the
implementation of the new LS curriculum in Uganda.
Research Objectives
1) Determine the perceived preparedness of lower secondary school teachers to
implement the new lower secondary curriculum.
2) Explore the school and teacher-factors that facilitate/hinder the implementation of
the new lower secondary curriculum.
3) Identify the support that lower secondary teachers need to improve their capacity
to implement the new LS curriculum.
|
Uganda |
2021-08-19 |
2024-08-19 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Christopher Dolan Gerald
ID:
|
"changing gender norms and gender-responsive humanitarian action in Ugandaâ€
REFNo: SS858ES
 To examine gendered norms, roles and power relations changed during and after forced displacement;
 To explore how existing knowledge on gender issues informed design of the current refugee response; and
 To find out implications for humanitarian agencies of observed changes in gender roles, norms and power relations
|
UK |
2021-08-17 |
2024-08-17 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Elizabeth Najjingo
ID:
|
Factors that influence false tooth extraction among children below two years in Isingiro, Southwestern Uganda.
REFNo: SS952ES
To explore alternatives that can be used instead of false tooth extraction,To explore outcomes of the practice false tooth extraction,To identify methods used for false tooth extraction in Isingiro district.,To explore factors responsible for false tooth extraction within Isingiro district.,To explore factors responsible for the practice of false tooth extraction and methods used in Isingiro district in South Western Uganda.,
|
Uganda |
2021-08-17 |
2024-08-17 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Munshi Sulaiman
ID:
|
Mobile money, privacy, security and women’s empowerment: Exploring the impact pathways of digital finance for women’s empowerment
REFNo: SS907ES
This research aims to assess the mechanisms (e.g. security and privacy) through which digital transfers may increase women’s agency and economic empowerment. The study will answer a number of research questions including:
• Are digital transfers more adequate instruments compared to cash transfers for improving women’s economic empowerment?
• Do digital transfers increase women’s privacy over financial information?
• Does privacy of information enhance the women’s enactment of choices?
• Does the secure nature of mobile money transfers significantly impact WEE outcomes?
• Which DFS pathways play a greater role in enhancing women’s agency and enactment of choices; security of money or privacy of information?
|
Bangladesh |
2021-08-17 |
2024-08-17 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|